iRadimed (NASDAQ:IRMD) Updates Q3 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its third quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.540-0.590 for the period, compared to the consensus EPS estimate of 0.530. The company issued revenue guidance of $23.0 million-$24.5 million, compared to the consensus revenue estimate of $23.7 million. iRadimed also updated its FY 2026 guidance to 2.090-2.240 EPS.

iRadimed Price Performance

NASDAQ IRMD opened at $90.86 on Friday. The company has a fifty day moving average price of $94.54 and a 200-day moving average price of $95.70. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 50.76 and a beta of 0.90. iRadimed has a 1 year low of $57.83 and a 1 year high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. The business had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, research analysts anticipate that iRadimed will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be given a $0.20 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is currently 43.72%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $120.00.

Insider Activity at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of iRadimed stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at approximately $195,922,500. The trade was a 0.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 21,250 shares of company stock worth $1,836,403. Corporate insiders own 34.60% of the company’s stock.

Key iRadimed News

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Boothbay Fund Management LLC purchased a new position in iRadimed during the third quarter worth about $279,000. Cerity Partners LLC purchased a new stake in iRadimed during the fourth quarter valued at about $261,000. Brevan Howard Capital Management LP bought a new position in shares of iRadimed during the 2nd quarter valued at about $260,000. PharVision Advisers LLC purchased a new stake in iRadimed in the third quarter worth approximately $257,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.